Phenotype of the infused 19-28z–transduced T cells
Patient ID . | CD4+ . | CD8+ . | CD28+CD27− . | CD28+CD27+ . | CD62L+ . | CCR7+ . | CD25+CD4+Foxp3+ . | Days in culture . |
---|---|---|---|---|---|---|---|---|
CLL-1 | 94 | 5 | 83.2 | 11.5 | 9.1 | ND | 1.2 | 17 |
CLL-2 | 96 | 5 | 86.1 | 6.1 | 15.5 | ND | 0.61 | 19 |
CLL-3 | 93 | 8 | 40.6 | 2 | 17.7 | ND | 2.4 | 18 |
CLL-4 | 99 | 0.7 | 86.9 | 5.9 | 34.4 | ND | 0.9 | 15 |
CLL-5 | 87 | 12 | 56.6 | 20.8 | 40 | 7.7 | 0.7 | 18 |
CLL-5 (CAR+) | 87.4 | 11.9 | 62.9 | 16.6 | 40.4 | 10.1 | ND | ND |
CLL-6 | 79 | 21 | 45.8 | 30.8 | 51.5 | 3.4 | 1.3 | 15 |
CLL-6 (CAR+) | 78.6 | 20.8 | 57 | 19.3 | 52 | 3.7 | ND | ND |
CLL-7 | 58 | 27 | 41.3 | 13.5 | 63.4 | 1.1 | 1.2 | 15 |
CLL-7 (CAR+) | 66.6 | 21.5 | 49.1 | 13.3 | 54.3 | 1.4 | ND | ND |
CLL-8 | 91.5 | 8.5 | 81.7 | 9.1 | 33.1 | 19.6 | ND | 16 |
CLL-8 (CAR+) | 90.3 | 9.7 | 82.4 | 7.8 | 28.1 | 16.6 | ND | ND |
ALL-1 | 74 | 26 | 43.4 | 16.5 | 64.3 | 1.3 | 1.7 | 11 |
ALL-1 (CAR+) | 62.8 | 25.6 | 52.3 | 15.9 | 78.1 | 1.3 | ND | ND |
ALL-2 | 52 | 48 | 5.2 | 84.8 | 94.8 | 47.4 | ND | 13 |
ALL-2 (CAR+) | 47.9 | 51.8 | 28.5 | 64.1 | 86.1 | 36.5 | ND | ND |
Patient ID . | CD4+ . | CD8+ . | CD28+CD27− . | CD28+CD27+ . | CD62L+ . | CCR7+ . | CD25+CD4+Foxp3+ . | Days in culture . |
---|---|---|---|---|---|---|---|---|
CLL-1 | 94 | 5 | 83.2 | 11.5 | 9.1 | ND | 1.2 | 17 |
CLL-2 | 96 | 5 | 86.1 | 6.1 | 15.5 | ND | 0.61 | 19 |
CLL-3 | 93 | 8 | 40.6 | 2 | 17.7 | ND | 2.4 | 18 |
CLL-4 | 99 | 0.7 | 86.9 | 5.9 | 34.4 | ND | 0.9 | 15 |
CLL-5 | 87 | 12 | 56.6 | 20.8 | 40 | 7.7 | 0.7 | 18 |
CLL-5 (CAR+) | 87.4 | 11.9 | 62.9 | 16.6 | 40.4 | 10.1 | ND | ND |
CLL-6 | 79 | 21 | 45.8 | 30.8 | 51.5 | 3.4 | 1.3 | 15 |
CLL-6 (CAR+) | 78.6 | 20.8 | 57 | 19.3 | 52 | 3.7 | ND | ND |
CLL-7 | 58 | 27 | 41.3 | 13.5 | 63.4 | 1.1 | 1.2 | 15 |
CLL-7 (CAR+) | 66.6 | 21.5 | 49.1 | 13.3 | 54.3 | 1.4 | ND | ND |
CLL-8 | 91.5 | 8.5 | 81.7 | 9.1 | 33.1 | 19.6 | ND | 16 |
CLL-8 (CAR+) | 90.3 | 9.7 | 82.4 | 7.8 | 28.1 | 16.6 | ND | ND |
ALL-1 | 74 | 26 | 43.4 | 16.5 | 64.3 | 1.3 | 1.7 | 11 |
ALL-1 (CAR+) | 62.8 | 25.6 | 52.3 | 15.9 | 78.1 | 1.3 | ND | ND |
ALL-2 | 52 | 48 | 5.2 | 84.8 | 94.8 | 47.4 | ND | 13 |
ALL-2 (CAR+) | 47.9 | 51.8 | 28.5 | 64.1 | 86.1 | 36.5 | ND | ND |
For patients CLL-1, CLL-2, CLL-3, and CLL-4, the CD4, CD8, and memory phenotypes were analyzed in 7-AAD− populations. For patients CLL-5, CLL-6, CLL-7, ALL-1, and ALL-2, the CD4, CD8, and memory phenotypes were analyzed in both 7-AAD− and CAR+ populations. All numbers are expressed in percentage of 7-AAD− or CAR+ populations as indicated.